Results 111 to 120 of about 455 (155)

Plasma Concentrations of Desethyl N-Acetylprocainamide in Patients Treated with Procainamide and N-Acetylprocainamide

Therapeutic Drug Monitoring, 1981
We describe a method for routinely measuring plasma concentrations of procainamide (PA), N-acetylprocainamide (NAPA) and desethyl N-acetylprocainamide (NAPADE) by high-performance liquid chromatography (HPLC). The method has been used together with mass spectrometry of the appropriate chromatographic fraction to demonstrate that NAPADE is a metabolite ...
T I, Ruo, J P, Thenot, G P, Stec, A J, Atkinson   +3 more
openaire   +2 more sources

Torsades de Pointes Due to N‐Acetylprocainamide

Pacing and Clinical Electrophysiology, 1985
A 66‐year‐old female with chronic renal failure received five doses of procainamide and developed marked QT interval prolongation and recurrent episodes of torsades de pointes. which were temporally related to high serum n‐acetylprocainamide (NAPA) levels and not to procainamide levels.
W G, Stevenson, J, Weiss
openaire   +2 more sources

Hemodynamic effects of N-acetylprocainamide in heart disease

Clinical Pharmacology and Therapeutics, 1982
In six normal subjects and 6 patients with primary cardiomyopathy, left ventricular performance was evaluated at rest and during isometric handgrip exercise after 4 days of oral N-acetylprocainamide (NAPA) at each of the three dosage levels (3, 4, 5, and 6 gm/day).
M H, Crawford, T M, Ludden, G T, Kennedy, M T, Sodums, R A, O'Rourke, K W, Amon   +5 more
openaire   +2 more sources

Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide

The American Journal of Cardiology, 1981
Eleven patients with chronic ventricular arrhythmias took part in a study of N-acetylprocainamide (NAPA), the major metabolite of procainamide, in order to characterize further NAPA's clinical pharmacology and antiarrhythmic action. The frequency of ventricular arrhythmia on 24 hour ambulatory electrocardiographic recordings was comparable on ...
R A, Winkle, P, Jaillon, R E, Kates, F, Peters   +3 more
openaire   +2 more sources

N-Acetylprocainamide kinetics and clinical response during repeated dosing

Clinical Pharmacology and Therapeutics, 1982
Kinetics of and clinical responses to N-acetylprocainamide (NAPA) were evaluated in 10 patients with chronic ventricular arrhythmias who had not responded to usual doses of currently available antiarrhythmic drugs. Kinetic data analysis was by measured NAPA concentrations (n = 149) collected during repeated dosing. Response was evaluated with serial 24-
J H, Rodman, A, Hurst, T, Gaarder, J, Cohen, R W, Jelliffe   +4 more
openaire   +2 more sources

Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease

Clinical Pharmacology and Therapeutics, 1980
N-Acetylprocainamide (NAPA) disposition kinetics was studied in eight patients with coronary artery disease. NAPA was given over a 45-min period by intravenous infusion, and blood samples were drawn at specified times for 24 hr. NAPA plasma levels were determined by a specific high-pressure liquid chromatography (HPLC) procedure and the concentration ...
R E, Kates, P, Jaillon, D S, Rubenson, R A, Winkle   +3 more
openaire   +2 more sources

Electrophysiologic effects of N-acetylprocainamide in human beings

The American Journal of Cardiology, 1981
The electrophysiologic properties of N-acetylprocainamide (NAPA) were studied in 10 patients undergoing cardiac catheterization. Each patient received two successive intravenous infusions: one loading infusion over 15 minutes and one maintenance infusion at a slower rate for 30 minutes.
P, Jaillon, D, Rubenson, F, Peters, J W, Mason, R A, Winkle   +4 more
openaire   +2 more sources

Tissue distribution of N-acetylprocainamide in rats.

Drug Metabolism and Disposition, 1981
The purpose of this study was to determine the distribution of N-acetylprocainamide (NAPA) in heart, kidney, and liver tissues of rats and their relationship to the plasma concentration after intravenous administration of the drug (100 mg/kg) to 24 Charles River rats. A specific HPLC procedure was used.
A, Yacobi, H F, Stampfli, C M, Lai, B L, Kamath   +3 more
openaire   +2 more sources

Torsade de pointes associated with elevated N-acetylprocainamide levels

American Heart Journal, 1985
N-acetylprocainamide (NAPA), the major metabolite of procainamide, has been shown to have separate antiarrhythmic and side effects from procainamide.l Torsade de pointes, a type of polymorphous ventricular tachycardia characterized by “twisting” of ventricular complexes around the isoelectric line and usually associated with QT prolongation,2 has been ...
H G, Stratmann, K E, Walter, H L, Kennedy   +2 more
openaire   +2 more sources

Procainamide, N-Acetylprocainamide, Antinuclear Antibody and Systemic Lupus Erythomatosus

Angiology, 1986
Long-term therapy with procainamide (PA) leads to the systemic lupus erythematosus syndrome (SLE) in about 30% of patients and 80% develop antinuclear antibodies. Acetylation of procainamide results in the formation of N-acetylprocainamide (NAPA) the propensity of which to induce SLE and to increase antinuclear antibodies is negligible while its ...
M M, Reidenberg, D E, Drayer
openaire   +2 more sources